Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
October 09, 2023 16:45 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
September 27, 2023 16:15 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
September 09, 2023 20:00 ET
|
Supernus Pharmaceuticals, Inc.
Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant medication in pediatric patients with...
Supernus to Participate in the Wells Fargo Healthcare Conference
August 31, 2023 17:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Bethany L. Sensenig Joins Supernus’ Board of Directors
August 21, 2023 09:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Second Quarter 2023 Financial Results
August 08, 2023 16:17 ET
|
Supernus Pharmaceuticals, Inc.
Qelbree® net product sales growth of 179% and 193% in the second quarter and first six months of 2023, respectively, compared to the same periods in 2022$31.0 million and $56.8 million of net...
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
July 24, 2023 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., July 24, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in the Jefferies Healthcare Conference
May 31, 2023 16:15 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2023 Financial Results
May 09, 2023 16:05 ET
|
Supernus Pharmaceuticals, Inc.
First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree® net product sales of $25.8 million, compared to $8.3 million in first quarter...
Supernus to Present at the Bank of America 2023 Health Care Conference
May 02, 2023 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...